氨磺必利治疗女性首发精神分裂症对照研究

摘要

Objective To explore the clinical efficacy and safety of amisulpride in the treatment of female first‐episode schizophrenia .Methods Eighty‐four female first‐episode schizophrenics were randomly as‐signed to two groups of 42 ones each ,research group took orally amisulpride and control group did risperi‐done for 7 weeks .Efficacies were assessed with the Brief Psychiatric Rating Scale (BPRS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scales (TESS) .Results Since the end of the 1st week the BPRS scores of both groups lowered more significantly compared with pretreat‐ment (P<0.01) ,at the end of the 7th week obvious effective and effective rate were respectively 95.2%and 100% in research and 92.9% and 100% in control group ,which showed no significant group difference (P>0.05) .Adverse reactions of both groups were mild ,but the incidence of tremor ,akathisia and myo‐tonia as well as the increase value of body mass were significantly lower in research than control group (P<0.05) .Conclusion Amisulpride takes effect rapidly ,has an evident effect ,higher safety and less in‐fluence on body mass in female schizophrenia ,and is favorable to the improvement of compliance of female patient .%目的：探讨氨磺必利治疗女性首发精神分裂症患者的临床疗效和安全性。方法将84例首发精神分裂症患者随机分为两组，每组42例，研究组口服氨磺必利治疗，对照组口服利培酮治疗，观察7周。采用简明精神病量表评定临床疗效，副反应量表评定不良反应。结果治疗1周末起两组简明精神病量表评分均较治疗前显著下降（P＜0.01），治疗7周末研究组显效率95.2％、有效率100％，对照组分别为92.9％、100％，两组比较差异无显著性（ P＞0．05）。两组不良反应均较轻，但研究组震颤、静坐不能、肌强直发生率及体质量增加值显著低于对照组（ P＜0.05）。结论氨磺必利治疗女性首发精神分裂症起效快，疗效显著，安全性高，对体质量影响较小，有利于提高女性患者的治疗依从性。